Literature DB >> 26942049

Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors.

Michele Ardolino1, David H Raulet1.   

Abstract

Recent extraordinary advances in cancer immunotherapy rely primarily on marshaling T cell responses. Here we discuss how NK cell responses can be amplified. We find that MHC I-deficient tumors induce anergy of NK cells but that cytokine therapy restores NK cell activity and increases the survival of mice bearing MHC I-deficient tumors.

Entities:  

Keywords:  NK cells; cancer immunotherapy; cytokines

Year:  2015        PMID： 26942049      PMCID： PMC4760323          DOI： 10.1080/2162402X.2014.1002725

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  MHC antigens and tumor escape from immune surveillance.

Authors:  F Garrido; I Algarra
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

Review 2.  Cytokine therapy.

Authors:  Antony Cutler; Frank Brombacher
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

Review 3.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

4.  Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.

Authors:  Michele Ardolino; Camillia S Azimi; Alexandre Iannello; Troy N Trevino; Lucas Horan; Lily Zhang; Weiwen Deng; Aaron M Ring; Suzanne Fischer; K Christopher Garcia; David H Raulet
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

5.  A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

Authors:  Norbert Vey; Jean-Henri Bourhis; Nicolas Boissel; Dominique Bordessoule; Thomas Prebet; Aude Charbonnier; Anne Etienne; Pascale Andre; François Romagne; Don Benson; Herve Dombret; Daniel Olive
Journal:  Blood       Date:  2012-09-21       Impact factor: 22.113

6.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Authors:  Francois Romagné; Pascale André; Pieter Spee; Stefan Zahn; Nicolas Anfossi; Laurent Gauthier; Marusca Capanni; Loredana Ruggeri; Don M Benson; Bradley W Blaser; Mariella Della Chiesa; Alessandro Moretta; Eric Vivier; Michael A Caligiuri; Andrea Velardi; Nicolai Wagtmann
Journal:  Blood       Date:  2009-06-24       Impact factor: 22.113

7.  Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.

Authors:  Aron M Levin; Darren L Bates; Aaron M Ring; Carsten Krieg; Jack T Lin; Leon Su; Ignacio Moraga; Miro E Raeber; Gregory R Bowman; Paul Novick; Vijay S Pande; C Garrison Fathman; Onur Boyman; K Christopher Garcia
Journal:  Nature       Date:  2012-03-25       Impact factor: 49.962

8.  The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses.

Authors:  Brendon J Coventry; Martin L Ashdown
Journal:  Cancer Manag Res       Date:  2012-08-02       Impact factor: 3.989

9.  Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment.

Authors:  Nathalie T Joncker; Nataliya Shifrin; Frédéric Delebecque; David H Raulet
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307
  9 in total
  2 in total

1.  Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors.

Authors:  Natalie K Wolf; Cristina Blaj; Lora K Picton; Gail Snyder; Li Zhang; Christopher J Nicolai; Chudi O Ndubaku; Sarah M McWhirter; K Christopher Garcia; David H Raulet
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-19       Impact factor: 12.779

Review 2.  Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors.

Authors:  Hamid Khodayari; Saeed Khodayari; Elmira Ebrahimi; Farimah Hadjilooei; Miko Vesovic; Habibollah Mahmoodzadeh; Tomo Saric; Wilfried Stücker; Stefaan Van Gool; Jürgen Hescheler; Karim Nayernia
Journal:  Cancer Immunol Immunother       Date:  2021-07-04       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.